These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 25816888

  • 1. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L, Knop FK, Vilsbøll T.
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Insulin degludec + liraglutide: a complementary combination.
    Stinkens K, Peene B, Mathieu C.
    Expert Opin Biol Ther; 2016 Sep; 16(9):1171-7. PubMed ID: 27484310
    [Abstract] [Full Text] [Related]

  • 4. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
    Simpson R, King A.
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):179-88. PubMed ID: 25697410
    [Abstract] [Full Text] [Related]

  • 5. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T, Vora J, Jarlov H, Kvist K, Blonde L.
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B, Mocarski M, Valentine WJ, Langer J.
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [Abstract] [Full Text] [Related]

  • 7. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M.
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
    Østergaard L, Frandsen CS, Dejgaard TF, Madsbad S.
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
    Harris S, Abrahamson MJ, Ceriello A, Charpentier G, Evans M, Lehmann R, Liebl A, Linjawi S, Holt RIG, Hosszúfalusi N, Rutten G, Vilsbøll T.
    Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, Rodbard HW, NN9068-3912 (DUAL-II) Trial Investigators.
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [Abstract] [Full Text] [Related]

  • 17. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
    Harris K, Nealy KL.
    Ann Pharmacother; 2018 Jan; 52(1):69-77. PubMed ID: 28799414
    [Abstract] [Full Text] [Related]

  • 18. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
    Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E.
    Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
    [Abstract] [Full Text] [Related]

  • 19. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
    Watada H, Kaneko S, Komatsu M, Agner BR, Nishida T, Ranthe M, Nakamura J.
    Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
    [Abstract] [Full Text] [Related]

  • 20. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I, Pettus JH, Santos Cavaiola T.
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.